CTMX Opportunity to hit 3.8 - 5.7 mark after the huge dropTheir recent study data ir.cytomx.com
Their ER PR ir.cytomx.com
Summary:
CytomX Therapeutics announces positive initial Phase 1a dose escalation data for monotherapy CX-904, a PROBODY® T-Cell Engager, demonstrating a favorable safety profile and encouraging efficacy in advanced pancreatic cancer